{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-130486","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.736020+00:00","generated_at":"2026-05-15T08:23:59.405669+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kezar Life Sciences to be acquired by Aurinia Pharma for $6.955 per share cash plus CVR","bullets":["Aurinia Pharma U.S. will commence a tender offer at $6.955/share cash plus one contingent value right (CVR) per share.","Tang Capital Partners, holding ~9% of shares, agrees to tender in support of the deal.","CVR holders may receive payments from excess net cash above $50M, Enodia APA proceeds, and milestones/royalties from zetomipzomib.","Closing expected in Q2 2026; conditions include minimum tender >50% and net cash ≥$50M.","Termination fee of $1.2 million payable by Kezar under specified circumstances, including a superior proposal."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-130486","json":"https://secwatch.observer/filing/0001193125-26-130486.json","markdown":"https://secwatch.observer/filing/0001193125-26-130486.md","text":"https://secwatch.observer/filing/0001193125-26-130486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000119312526130486/0001193125-26-130486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000119312526130486/d106892d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:23:59.405669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2379e4d44e0c3596a0767782c58066b34dbb2f6c","claim":"Kezar Life Sciences, Inc. entered into Agreement and Plan of Merger with Aurinia Pharma U.S., Inc. valued at $6.955 per Share (effective 2026-03-30).","evidence_excerpt":"On March 30, 2026, Kezar Life Sciences, Inc., a Delaware corporation (the “ Company ” or “ Kezar ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Aurinia Pharma U.S., Inc., a Delaware corporation (“ Parent ” or “Aurinia”), Aurinia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ” and together with Parent, the “ Buyer Entities ”), and, solely for purposes of Section 10.13 of the Merger Agreement, Aurinia Pharmaceuticals Inc., a company incorporated under the laws of the Province of Alberta (“ Ultimate Parent ”), and the parent entity of Parent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000119312526130486/0001193125-26-130486-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Aurinia Pharma U.S., Inc."},{"label":"Value","value":"$6.955 per Share"},{"label":"Effective","value":"2026-03-30"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}